Stoke TherapeuticsSTOK
About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Employees: 128
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
9% more funds holding
Funds holding: 118 [Q3] → 129 (+11) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
0.96% less ownership
Funds ownership: 110.57% [Q3] → 109.61% (-0.96%) [Q4]
5% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 41
10% less capital invested
Capital invested by funds: $715M [Q3] → $640M (-$75.1M) [Q4]
86% less call options, than puts
Call options by funds: $38K | Put options by funds: $263K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Joseph Stringer 23% 1-year accuracy 27 / 118 met price target | 123%upside $22 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 102 / 354 met price target | 376%upside $47 | Buy Reiterated | 19 Mar 2025 |
Chardan Capital Rudy Li 17% 1-year accuracy 1 / 6 met price target | 143%upside $24 | Buy Maintained | 19 Mar 2025 |
Financial journalist opinion
Based on 3 articles about STOK published over the past 30 days
